We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu
Trial record 1 of 2 for:    optejet | presbyopia
Previous Study | Return to List | Next Study

Safety & Efficacy of Pilocarpine Ophthalmic Spray for Temporary Improvement of Near Vision in Presbyopic Adults (VISION-2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT05114486
Recruitment Status : Recruiting
First Posted : November 10, 2021
Last Update Posted : May 9, 2022
Information provided by (Responsible Party):
Eyenovia Inc.

Brief Summary:
Volunteer participants are evaluated for eligibility during a Screening Visit; those meeting study inclusion/exclusion criteria are scheduled for 2 treatment visits. At each treatment visit, 1 of the 2 study treatments is self-administered to both eyes. Afterwards, efficacy and safety assessments are performed over a 3-hour period.

Condition or disease Intervention/treatment Phase
Presbyopia Drug: Pilocarpine Ophthalmic Drug: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 139 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3 Study of the Safety and Efficacy of 2% Pilocarpine Ophthalmic Spray Administered With the Optejet® Microdose Dispenser for Temporary Improvement of Near Vision in Adults With Presbyopia
Actual Study Start Date : November 3, 2021
Estimated Primary Completion Date : June 30, 2022
Estimated Study Completion Date : June 30, 2022

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Pilocarpine 2% Ophthalmic Spray
2% pilocarpine ophthalmic spray administered with the Optejet dispenser
Drug: Pilocarpine Ophthalmic
Pilocarpine 2% ophthalmic spray administered with the Optejet microdose dispenser
Other Name: MicroLine

Placebo Comparator: Placebo Spray
Placebo ophthalmic spray administered with the Optejet dispenser
Drug: Placebo
Vehicle ophthalmic solution administered with the Optejet microdose dispenser

Primary Outcome Measures :
  1. Proportion of subjects gaining ≥ 15 letters in mesopic, high contrast, binocular distance corrected near visual acuity (DCNVA) with ≤ 5 letter loss in mesopic, high contrast, binocular distance visual acuity (DVA) [ Time Frame: 120 minutes post-dosing ]
    The proportion of subjects gaining ≥ 15 letters in mesopic, high contrast, binocular DCNVA with ≤ 5 letter loss DVA as compared to baseline.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   40 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Primary Inclusion Criteria:

  • Poor near vision impacting daily living that requires near correction
  • Best-corrected distance visual acuity (BCDVA) of 0.0 logMar or better
  • Manifest refraction spherical equivalent ≥ -2.00 Diopters (D) and ≤ +2.00 D
  • Monocular DCNVA between 0.4 and 0.7 logMAR, inclusive
  • In need of near addition power < +2.00 D to achieve BCNVA of 0.0 logMAR

Primary Exclusion Criteria:

  • Diagnosis of glaucoma or ocular hypertension
  • Narrow iridocorneal angles
  • History of intraocular surgery, refractive surgery, laser treatment, or iris surgery
  • Clinically significant abnormality of cornea, lens, retina, ciliary body, or iris
  • Presence/history of a severe/serious ocular condition or any other unstable medical condition
  • Presence or history of manifest strabismus, amblyopia, or nystagmus
  • Current active eye disease for which topical or systemic ophthalmic medication is necessary, except for dry eye syndrome managed using artificial tears
  • Clinically significant external ocular inflammation within 30 days of Screening Visit
  • Current use or history of rigid gas permeable (RGP) contact lens use within 30 days of Screening Visit
  • Known pilocarpine allergy or contraindication to use of pilocarpine
  • Presence or history of congenital heart anomaly, valve disease, or other cardiac disease
  • Disabling arthritis or limited motor coordination that would limit the subject's ability to self-administer study solution using the Optejet

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05114486

Layout table for location contacts
Contact: Greg Bennett, MSEd 650-504-2005 gbennett@eyenoviabio.com
Contact: Ginger Clasby, MS 714-269-8838 gclasby@eyenoviabio.com

Layout table for location information
United States, California
VISION-2 Study Site #57 Recruiting
San Diego, California, United States, 92131
Contact: VISION-2 Study Coordinator    858-530-2800      
United States, Connecticut
VISION-2 Study Site #59 Recruiting
Fairfield, Connecticut, United States, 06890
Contact: VISION-2 Study Coordinator    631-626-6389      
United States, Kentucky
VISION-2 Study Site #56 Recruiting
Louisville, Kentucky, United States, 40206
Contact: VISION-2 Study Coordinator    502-512-8458      
United States, Ohio
VISION-2 Study Site #19 Recruiting
Columbus, Ohio, United States, 43210
Contact: VISION-2 Study Coordinator    614-292-8858      
United States, Pennsylvania
VISION-2 Study Site #58 Recruiting
Philadelphia, Pennsylvania, United States, 19141
Contact: VISION-2 Study Coordinator    215-276-6034      
United States, South Dakota
VISION-2 Study Site #62 Recruiting
Sioux Falls, South Dakota, United States, 57018
Contact: VISION-2 Study Coordinator    605-371-7075      
United States, Tennessee
VISION-2 Study Site #55 Recruiting
Memphis, Tennessee, United States, 38119
Contact: VISION-2 Study Coordinator    901-761-4620      
United States, Texas
VISON-2 Study Site #60 Recruiting
Austin, Texas, United States, 78731
Contact: VISION-2 Study Coordinator    512-465-4400      
United States, Utah
VISION-2 Study Site #61 Recruiting
Draper, Utah, United States, 84020
Contact: VISION-2 Study Coordinator    801-988-7436      
Sponsors and Collaborators
Eyenovia Inc.
Layout table for investigator information
Study Chair: Tsontcho (Sean) Ianchulev, MD, MPH Eyenovia Inc.
Layout table for additonal information
Responsible Party: Eyenovia Inc.
ClinicalTrials.gov Identifier: NCT05114486    
Other Study ID Numbers: EYN-PRS-PI-32
First Posted: November 10, 2021    Key Record Dates
Last Update Posted: May 9, 2022
Last Verified: May 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Refractive Errors
Eye Diseases
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Muscarinic Agonists
Cholinergic Agonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action